Gyros AB announces license and development agreement with Fujirebio Inc, Japan

29-Nov-2004

Gyros AB has signed a non-exclusive license and development agreement with Fujirebio Inc. for diagnostic applications using Gyros' proprietary Compact Disc technology.

Under the terms of the agreement, Fujirebio will investigate combining Gyros' Compact Disc technology with its own chemiluminescence immunoassay platform, in order to develop a new system for diagnostic applications. Jan Würtz, CEO & President of Gyros AB said; "Gyros has now reached an important milestone in its effort of commercialize its unique microfluidics technology for clinical diagnostic applications. Miniaturization and integration of immunoassays using Gyros' Compact Disk format could give significant productivity gains compared to traditional ways of working."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance